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Abstract
Background Patients with end-stage renal disease
(ESRD) require phosphate binders for hyperphosphatemia
and erythropoiesis-stimulating agents (ESAs) and intra-
venous (IV) iron for anemia. Ferric citrate (FC) is a novel,
iron-based phosphate binder that increases iron stores and
decreases IV iron and ESA usage while maintaining
hemoglobin levels, and may decrease the cost of ESRD
care. The study objectives were to (1) quantify differences
in ESA and IV iron usage among ESRD patients receiving
FC compared with active control (AC) (sevelamer car-
bonate and/or calcium acetate) on the basis of data from a
52-week phase III clinical trial and (2) standardize trial
data to the general United States (US) ESRD population
and calculate the potential impact of FC on ESRD
cost/patient/year in the USA.
Study Design The study was a randomized, controlled
clinical trial.
Setting and Population A total of 441 adult subjects with
ESRD who received FC or AC for 52 weeks were
included.
Model, Perspective, and Timeline Differences in ESA
and IV iron usage between the treatment groups were
modeled over time using generalized linear mixed models
and zero-inflated Poisson models. Trends were modeled via
logarithmic curves, and utilization patterns were applied to
the general dialysis population to estimate expected
resource savings.
Outcomes Study outcomes were costs saved/patient/year
using FC versus AC (US dollars).
Results Our model suggests an annual decrease of
129,106 U of ESAs and 1960 mg of IV iron per patient in
the second year after a switch from AC to FC. Applying
2013 Medicare pricing, this would save $1585 in ESAs and
$516 in IV iron: a total of $2101/patient/year; these savings
would be expected to double for managed care plans.
Limitations The projections were made on 1 year of trial
data.
Conclusions Phosphate binding with FC reduces IV iron
and ESA usage. Given the high cost burden of ESRD, our
model demonstrates significant potential cost savings.
Trial Registration ClinicalTrials.gov (NCT01191255)
http://clinicaltrials.gov/ct2/show/NCT01191255.
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Key Points
Hyperphosphatemia and anemia are nearly universal
in patients with end-stage renal disease (ESRD), and
are one of the more costly aspects of ESRD-related
care.
In a phase III, 52-week clinical trial in ESRD study
subjects on dialysis, ferric citrate, an FDA-approved
iron-based phosphate binder, significantly reduced
erythropoiesis-stimulating agent (ESA) and
intravenous (IV) iron use when compared with study
subjects receiving a non-iron-based phosphate binder
(‘‘active control’’).
The costs savings we predict in our report are from
analyses of the IV iron and ESA usage from that
phase III trial over the entire 52-week active-control
study period.
The percentage of subjects on ferric citrate receiving
IV iron decreased, declining from nearly 60 % at the
beginning of the study to approximately 20 % by the
end of the study.
In fourth-quarter 2013 Medicare pricing terms, these
differences would equate to $1585 in ESAs and $516
in IV iron, for a total saving of $2101/patient/year
for dialysis centers, and twice that, $4202/patient/
year, for managed care plans.
1 Introduction
Dietary modifications and treatment with dialysis are usu-
ally ineffective strategies to control serum phosphorus to
target levels in patients with end-stage renal disease
(ESRD). Oral phosphate binders, therefore, become an
important adjunct in the care of the majority of these
patients [1]. Oral phosphate binders include calcium car-
bonate, calcium acetate, sevelamer, lanthanum carbonate,
and aluminum hydroxide. While each of these is effective
in binding dietary phosphorus in the gastrointestinal tract,
they have a number of differences in tolerability and
potential side effects [2–4].
Ferric citrate (FC) is a novel, iron-based, oral phosphate
binder that has been shown in clinical trials to provide safe
and effective management of serum phosphorus in subjects
with ESRD [5–10]. Similar to other binders, FC binds
dietary phosphorus in the bowel lumen; the insoluble ferric
phosphate product then precipitates and is subsequently
excreted. Although formal pharmacokinetic studies have
not been performed, examination of serum iron parameters
has shown that there is also systemic absorption of iron
from FC [11].
Like hyperphosphatemia, anemia is nearly universal in
patients with ESRD and is one of the most costly aspects of
ESRD-related care [12]. Erythropoiesis-stimulating agent
(ESA) dose requirements are less when patients have
adequate levels of circulating iron; thus, intravenous (IV)
iron is commonly administered to patients receiving ESAs
[13–15].
Primary analysis of the 52-week active-control (AC)
period of the phase III study demonstrated that the use of
FC significantly increased serum ferritin and transferrin
saturation compared with AC, and reduced IV iron and
ESA requirements in subjects receiving FC while main-
taining hemoglobin levels [16, 17]. Given the costs of
managing anemia, the use of FC as a phosphate binder for
patients with ESRD may also have an impact on the cost of
caring for patients with ESRD. This report presents models
to determine the potential cost savings associated with the
reduced ESA and IV iron utilization seen in the pivotal
phase III trial of FC compared with AC.
2 Materials and Methods
2.1 Clinical Trial
Data for these analyses were drawn from the 52-week AC
period of a phase III, international, multicenter, AC and
placebo-controlled, randomized, open-label trial of the
efficacy and safety of FC as a treatment for hyperphos-
phatemia in subjects with ESRD (NCT01191255) [8, 16].
The institutional review board at the Clinical Coordinating
Center at Vanderbilt University and each clinical site
approved the initial trial from which the data for this study
was obtained. All subjects gave written informed consent
before any investigational procedures, and the trial was
conducted in accordance with the Declaration of Helsinki
and good clinical practice.
After a 2-week washout period from all phosphate-
binding agents, subjects were randomly assigned in a 2:1
ratio to receive FC or AC, which consisted of study-sup-
plied calcium acetate and/or sevelamer carbonate. A total
of 441 subjects at 60 study sites in the USA and Israel were
randomized. During the 52-week AC period, binder dosing
was titrated to a goal serum phosphorus level between 3.5
and 5.5 mg/dL.
2.2 Calculation of Utilization
Intravenous iron and ESA usage in each treatment arm were
calculated by dividing the 52-week AC period into thirteen
28-day periods. This provided a more uniform distribution
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of dosing periods, allowing us to match trial data with the
weekly totals reported by the United States Renal Data
System (USRDS) for 2011 [18]. Case report forms (CRFs)
from study visits were used to define treatment episodes
(start date to stop date on the CRF) for each medication.
Average daily doses for each treatment episode were cal-
culated and then divided among specific 28-day periods in
the study. A weighted average for each 28-day period was
calculated to allow direct comparisons of dose. For their
data to qualify for inclusion in a given 28-day period, the
subject was required to have spent at least 15 days of the
period as active in the study and on assigned therapy. Total
dose for subject-months, with 15–27 days of included data,
was rescaled to the expected value over 28 days. Darbe-
poetin units were converted to epoetin alfa-equivalent units
(200 U per microgram of darbepoetin) [8, 16]. Subjects
contributed time and data for only those periods in which
they were active in the study and receiving their randomly
assigned phosphate binder treatment.
2.3 Reporting Data and Statistical Significance
Differences between the FC and AC arms in ESA and IV
iron dose were calculated for each 4-week period for three
values: percentage of subjects receiving the drug, mean and
standard deviation of dose among those receiving the drug,
and mean and standard deviation of overall utilization
across all subjects (including those with 0 dose). Statistical
analysis of percentage data was conducted using general-
ized linear mixed models, which allow for logistic mod-
eling of non-normal data with correlations [19]. These data
were zero-inflated; a significant proportion of subjects
([15 %) had no administered doses in a given 4-week
period. For this reason, overall utilization was considered
to be the most useful continuous comparator. The signifi-
cance of differences between the groups was modeled
using a zero-inflated Poisson (ZIP) model with degrees of
freedom and standard errors adjusted using the Kenward–
Roger method [18]. Doses over days 1–28 of the study
were used for each subject as their starting value, and
significance was assessed in the following 4-week periods.
Demographic comparisons between treatment groups were
made using unpaired t tests for continuous variables, such
as weight and age, and Chi-square tests for categorical
variables, such as race and gender.
2.4 Estimates of Economic Impact
Percentage differences between the treatment arms were
mapped to USRDS data for ESA and IV iron use from 2011
(reference population) [18], the latest available and a match
for the time frame of this 2010–2012 study. Any differ-
ences in utilization between the FC and AC arms were
standardized to the 2011 USRDS reference population. The
time periods of the study and the USRDS data do not
precisely match because of variability in enrollment dates
for the study (starting in December 2010), but the overall
temporal trend was considered to be relevant.
Since the changes in IV iron and ESA usage over time
were nonlinear in the phase III trial and the USRDS data,
we utilized logarithmic regression analysis to create curves
to estimate usage patterns over time, modeling mean dose
for those receiving the drug, percentage of subjects
receiving the drug, and mean utilization for all subjects.
Values for the treatment groups were projected beyond the
trial period under two different assumptions: the achieve-
ment of a steady-state and a continued change along the
same curve. Estimates of differences in ESA and IV iron
utilization between the groups for 1 or 2 years were gen-
erated on the basis of the assumption that all patients
remain on therapy for the duration of that time period.
Thus, variability (e.g., standard deviation) was not directly
calculable for these economic estimates.
For a general estimate of the economic impact of dif-
ferences in medication utilization among Medicare
patients, we applied fourth quarter (Q4) 2013 Medicare
average sale prices (ASPs) plus price changes equal to
those seen in published ASPs in 2013 (?9.4 % for ESA;
-3.2 % for IV iron sucrose) [20, 21]. In the case of
Medicare, under the current bundle system, these savings
would be realized by dialysis providers. We conservatively
estimated the economic impact on commercial payers by
doubling these figures [22, 23]. We modeled annual per-
patient utilization and cost differences for the second year
(and projected following years) after a theoretical switch
from AC to FC for both Medicare and commercial pay
patients. All costs and savings are presented in US dollars.
3 Results
3.1 Demographics
Among the 438 subjects in this population (those among the
441 randomized subjects who received at least one dose of
study drug), no notable differences were found with regard
to age, sex, weight, race, or ethnicity in the AC versus FC
groups (Table 1). Of the 289 subjects assigned to FC treat-
ment, 277 (95.8 %) completed at least 15 days of a 4-week
period and had valid data on injectable medications. In the
AC group, 145 (97.3 %) of 149 met these requirements.
3.2 Erythropoiesis-Stimulating Agent Utilization
Both the percentage of subjects receiving ESAs and the
mean dose for those subjects were similar in the first
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4-week period of the study (Table 2). During the
remainder of the 52 weeks, a gap in ESA utilization
between the two treatment groups emerged due to dif-
ferences in both the relative percentage of subjects
receiving ESAs and the mean dose administered over the
period among those receiving an ESA, primarily the
latter.
In the FC group, mean dose for subjects receiving ESAs
in a given 4-week period declined more precipitously than
in the AC group. The differences in overall per-subject
ESA use between the FC and AC groups reported in
Table 2 take into account differences in both doses and
percentage use and provide the best comparison of uti-
lization. These reductions ranged from 5000 to 10,000 U
per 4-week period over the course of the study. ZIP models
indicated that between-group differences were highly sig-
nificant (P\ 0.001) at all time points assessed (peri-
ods 2–13). Total per-subject ESA use was 74,194 U lower
in the FC group compared with the AC group across the 52
weeks of the trial.
Table 1 Baseline
characteristics
FC (n = 292)a AC (n = 149)
Age n 289 149
Mean (SD) 54.8 (13.38) 53.7 (13.01)
Sex Female 108 (37.4 %) 62 (41.6 %)
Male 181 (62.6 %) 87 (58.4 %)
Modality Hemodialysis 278 (96.2 %) 146 (98.0 %)
Peritoneal dialysis 11 (3.8 %) 3 (2.0 %)
Weight (kg) n 286 148
Mean (SD) 93.4 (27.51) 89.6 (24.05)
Race Black or African American 154 (53.3 %) 78 (52.3 %)
White/Caucasian 121 (41.9 %) 62 (41.6 %)
Other 14 (4.8 %) 9 (6.0 %)
AC active control, FC ferric citrate, SD standard deviation
a Three patients assigned to the FC group did not receive study drug
Table 2 ESA utilization













SD, U Percentage difference
in mean per-subject








with FC, applying trial
results to USRDS, U
1–4 81.6 45,113 42,292 80.9 44,588 47,988 -2.2 83.7 61,920 -1127
5–8 77.3 43,792 45,126 81.8 50,110 59,881 17.4 83.8 62,906 9174
9–12 82.4 41,458 48,771 81.2 46,254 56,737 9.0 83.5 62,845 4719
13–16 78.5 41,879 51,190 75.4 49,426 58,838 11.7 84.2 62,349 6163
17–20 77.5 36,405 43,268 81.3 47,348 58,307 26.6 84.3 59,663 13,381
21–24 78.6 36,848 46,567 82.3 41,167 39,796 14.5 84.1 60,712 7387
25–28 77.9 36,851 43,401 84.3 40,146 37,046 15.1 83.5 57,881 7318
29–32 79.3 35,852 43,379 81.7 39,432 42,616 11.8 81.7 54,093 5196
33–36 75.2 34,450 40,311 84.0 37,418 34,880 17.6 80.1 51,276 7209
37–40 76.7 32,484 38,171 80.2 42,496 41,306 26.8 80.3 49,989 10,767
41–44 74.7 33,770 41,305 81.7 38,816 36,565 20.4 81.0 51,609 8546
45–48 72.0 36,105 43,271 81.7 40,417 38,332 21.2 81.0 49,839 8561
49–52 71.4 33,210 37,266 75.0 42,116 41,888 25.0 81.0 52,033b 10,529b
AC active control, ESA erythropoiesis-stimulating agent, FC ferric citrate, SD standard deviation, USRDS United States Renal Data System
a Difference in mean utilization statistically significant (P\ 0.05) in zero-inflated Poisson model for all but first time period
b Per-patient utilization projected via logistic trend line
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Temporal trends for both treatment groups and USRDS
data, estimated by logistic regression, are presented in
Fig. 1 along with estimates of reductions in ESA utilization
that might be expected in subjects who switch from current
phosphate binders to FC. Throughout the study, mean
doses for subjects receiving ESAs were substantially lower
in the study-eligible population than those reported by the
USRDS. When standardized to the USRDS reference
population, the trial-based savings of 74,194 U per subject
over the first year rose to 97,824 U per subject.
Based on the regression model, the reduction in
USRDS-adjusted utilization would project to 140,533 U
per patient in the second year of FC therapy (Fig. 1).
Alternatively, if at the end of the trial period a steady-state
difference between the groups was assumed, the total
reduction in year 2 was expected to be 129,106 U per
subject. Based on Medicare pricing at the end of 2013, the
adjusted cost difference for the steady-state estimate would
be $1585/patient/year.
3.3 Intravenous Iron Utilization
The percentage of subjects receiving IV iron and the mean
dose received were similar between the two treatment
groups in the first 4-week period (Table 3). As with ESAs,
a gap in IV iron utilization between the two treatment
groups emerged during the remainder of the 52 weeks of
the study. In this case, these differences were primarily due
to the relative percentage of subjects in each group
receiving IV iron. In the FC group, the percentage of
subjects receiving IV iron in a given 4-week period
declined steadily over the course of the study, falling from
58.8 % in the first period to between 19.3 and 22.7 % per
28 days over the last 20 weeks of the 52-week period.
Differences in the percentage of subjects receiving
IV iron between the two groups were statistically signifi-
cant starting in month 3 and continuing through to the end
of the study (P\ 0.05 for month 3 and P\ 0.01 for
months 4–13). The mean dose administered to subjects
receiving IV iron was also lower in the FC group over the
period. Differences in overall utilization between the FC
and AC groups, taking into account reduced percentages
and differences in mean dose, are presented in Table 3.
According to the ZIP model, total utilization was signifi-
cantly different between the groups in all but two 4-week
periods (8 and 11). The mean total per-subject IV iron
utilization was 677.1 mg lower in the FC than in the AC
group across the 52-week AC period of the trial.
Temporal trends in total utilization for both treatment
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Fig. 1 Phase III trial-based and projected ESA utilization with USRDS-standardized differences. AC active control, ESA erythropoiesis-
stimulating agent, FC ferric citrate, USRDS United States Renal Data System
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logistic regression. These models are presented in Fig. 2
along with estimates of reductions in IV iron use that might
be expected in patients who switch from current phosphate
binders to FC. When standardized to the reference USRDS
population, the trial-based savings of 677.1 mg per subject
over the year rises to 1407.7 mg per subject.
Table 3 IV iron utilization






























with FC, applying trial
results to USRDS, U
1–4 58.8 237.3 213.8 61.9 248.0 195.49 9.1 71.3 356.7 23.0
5–8 50.6 258.5 216.2 57.8 261.1 202.97 13.4 72.7 353.3 34.4
9–12 43.5 217.8 180.5 57.9 253.4 207.89 35.4a 77.0 360.0 98.3
13–16 39.4 195.2 180.7 58.0 245.7 195.49 46.1a 77.5 335.0 119.6
17–20 28.7 187.9 157.5 55.5 239.6 197.97 59.4a 77.7 356.7 164.8
21–24 26.6 258.0 253.7 52.4 280.1 233.29 53.2a 77.5 346.7 142.9
25–28 25.4 236.1 210.0 48.8 255.6 218.34 51.8a 78.0 321.7 129.9
29–32 23.2 204.3 207.3 43.3 207.5 155.63 47.3 74.5 348.3 122.7
33–36 19.9 219.3 179.1 38.1 237.6 194.53 51.8a 71.0 305.0 112.1
37–40 19.3 271.8 254.6 35.9 254.8 229.74 42.5a 71.0 313.3 94.6
41–44 22.6 222.2 176.2 40.0 223.9 158.99 44.0 69.0 320.0 97.1
45–48 22.7 261.1 206.5 44.1 284.0 217.15 52.8a 238.0b 125.6
49–52 19.9 230.9 227.0 38.5 300.7 240.15 60.3a 236.8b 142.8
AC active control, FC ferric citrate, IV intravenous, SD standard deviation, USRDS United States Renal Data System
a Difference in mean utilization statistically significant (P\ 0.05) in zero-inflated Poisson model
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R  = 0.30
R  = 0.56
Fig. 2 Phase III trial-based and projected IV iron utilization with USRDS-standardized differences. AC active control, FC ferric citrate, IV
intravenous, USRDS United States Renal Data System
276 R. A. Rodby et al.
If the differences between treatment groups were to
continue to widen in year 2 after initiation of FC (as in
Fig. 2), the reduction in USRDS-standardized utilization
would increase to 2267.8 mg per patient. If a steady-state
difference between the groups was assumed at the end of
the trial period, the total reduction during year 2 was
expected to be 1960.6 mg. Based on Medicare pricing at
the end of 2013, the adjusted cost difference under this
steady-state estimate would be $516/patient/year.
4 Discussion
This analysis details substantially reduced utilization of
anemia-related medications among subjects receiving FC
compared with AC. These findings, when applied to the
general US dialysis population, translate into significant
health care dollar savings.
At the end of the 52-week, AC period of the trial, the
FC-treated group was, on average, receiving 20–25 % less
ESA per subject than the AC-treated group. Reductions in
ESA use over time were also found in the AC group, but
these reductions were far less substantial and in line with
real-world trends documented in the USRDS data.
Between-group differences were highly significant
(P\ 0.001) at all time points assessed.
The percentage of FC-treated subjects receiving IV iron
in a given 4-week period declined from nearly 60 % to
approximately 20 % by the end of the study. Over the last
40 weeks, total IV iron usage in the FC group was less that
50 % of that in the AC group. Month-by-month differences
were statistically significant (P\ 0.05) for all but two
periods (8 and 11). This inconsistency may be due to bolus
dosing of iron and the instability of short-term averages in
a relatively small pool (fewer than 40 subjects in each
group were receiving IV iron by the end of the study).
Logistic regression models indicated that these differ-
ences in overall utilization continue into the second year of
FC treatment. These differences remained even under a
steady-state assumption, suggesting an annual saving of
129,106 U of ESA (as epoetin alfa equivalents) and
1960.6 mg of IV iron per patient in the second year and
onwards.
The ESA and IV iron sparing effect of FC should impact
public and private payers as well as dialysis clinics.
Although federal law allows for Medicare coverage of
ESRD treatment, private insurance remains the primary
payer for the first 30 months of dialysis for patients who
have it in place [23]. Thus, it is appropriate to estimate
savings for both the Medicare-covered patient as well as
those covered by private insurance or some other means.
Reduced use ESA and IV iron among Medicare
patients would primarily benefit dialysis providers, as
these expenses are included in the ESRD Prospective
Payment System (the ‘‘Bundle’’) [18]. Reduced use
among patients with managed care plans would primarily
benefit the plans themselves while slightly reducing
profits for dialysis providers. Commercial payers reim-
burse dialysis centers directly for IV medication use and
do so at a considerably higher rate than the price of the
drugs, according to published Medicare-based figures. The
largest dialysis organizations (DaVita and Fresenius) both
report that the commercial reimbursement rate for them is
at least two times greater than the Medicare ASP for
injectable medications administered at the dialysis center
[22, 23].
In Q4 2013 Medicare pricing terms, these differences
would equate to $1585 in ESAs and $516 in IV iron, for a
total saving of $2101/patient/year for dialysis centers, and
twice that, $4202/patient/year, for managed care plans.
For these calculations and projections, the patient pop-
ulation was limited to those who were active in the study
and receiving their initially assigned phosphate binder. The
decline in the percentage of subjects receiving ESAs in the
AC group matched trends in 2011, according to USRDS
data, although a slightly lower percentage of subjects in the
AC group received ESAs in any given period
(75.0–84.3 %) than would be expected from USRDS data
(80.1–84.3 %) [18]. Throughout the study, the percentage
of subjects receiving IV iron in the AC group was lower
than that in the 2011 USRDS population. Doses received
for subjects taking IV iron did not show a consistent pat-
tern, but were generally lower in the AC group than in
USRDS data.
Reductions in utilization were applied to a roughly
contemporary reference population based on USRDS data
[18]. The subjects in the study were generally representa-
tive of the US dialysis population as evidenced by the
prevalence of diabetes and cardiovascular disease in the
trial cohort [16]. However, as is the case in all study
populations, there were also some differences. The mean
age in the USRDS 2011 reference population was 63 for
hemodialysis patients versus 55 in the study population,
and the USRDS percentage of subjects aged 65 years and
older was 43.9 % versus 20.5 % in the study. The gender
breakdown, however, was similar; 57 % of reference
USRDS hemodialysis patients were male, while 58 % were
male in the study [18]. It was also codified in the entry
criteria that subjects must have an estimated[1-year life
expectancy as determined by each site’s primary investi-
gation (PI). It is possible that there will be differences in
the impact of FC on ESA and IV iron usage in the wider
dialysis population. The USRDS-adjusted estimates depend
on the assumption that the percentage reductions in uti-
lization would apply equally to all dialysis patients.
However, this has not been substantiated.
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Estimates also assumed a predictable, modest decline in
ESA and IV iron utilization in the general US ESRD
population continued in the year after the study (2012).
Actual secular trends may modify these estimates. In
addition to the savings we report here relating decreased
ESA and IV iron usage, we also found that the use of FC
was associated with a reduction in hospitalization rates and
subsequent hospitalization costs, predicting a saving of
$3002/patient/year when using FC [24]. The cost of binders
is not accounted for in this analysis. It would be expected
that FC would cost more than generic calcium acetate and
sevelamer, and that this may offset some of the impact
associated with the aforementioned savings predicted from
decreased ESA and IV iron usage as well as the predicted
savings associated with fewer hospitalizations. It was not
the authors’ intent to model each and every one of these
factors in this analysis, although it is planned to be done.
This will require a more sophisticated pharmacoeconomic
analysis considering all of these factors and should include
a number of sensitivity analyses, especially since drug
pricing and what patients actually pay are two different
things altogether. Fortunately, the primary trial data reports
the actual binder dosing requirements to achieve equivalent
levels of serum phosphorus [16].
The primary trial was open label. The iron in FC causes
the stools to become dark, and thus there was no way
around this but to be open-label. Since both treatment
groups in the primary trial had similar achieved phosphorus
levels and essentially similar pill usage to achieve those
levels (by pill counts), we do not feel that the open-label
nature of the study impacted the reliability of the results
[16]. The trial was based on 52 weeks of therapy. While
there is no reason to believe that the efficacy of FC as a
phosphorus binder would lessen beyond that time frame,
longer term tolerability is yet to be determined.
Ferric citrate provides effective control of serum phos-
phorus in ESRD patients while increasing measures of iron
[16, 17]. The accompanying reductions in the utilization of
ESAs and IV iron in our study population suggest that FC
may also prove to be a valuable tool for anemia management
with the potential of providing cost savings to the health care
system. Providing care to the ESRD patient costs $87,945
patient/year [18]. Patients with ESRD represent 1.4 % of
Medicare patients but utilize 7.2 % of Medicare spending
[18]. Thus, anymaneuver that could decrease costs would be
welcomed in our current economic environment.
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